一、临床肿瘤杂志 (2023年第73卷第5期)

September/October 2023 - Volume 73 - Issue 5 (2023年9/10月第73卷第5期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2023/73/5

二、柳叶刀 (2023年第402卷第10404-10408期)

（一）02 September 2023 - Volume 402 - Issue 10404 (2023年9月2日第402卷第10404期)
https://www.thelancet.com/journals/lancet/issue/vol402no10404/PIIS0140-6736(23)X0035-X

COMMENT（评论）
1. Atogepant，首个预防性治疗偏头痛的口服药物
(Atogepant, the first oral preventive treatment for chronic migraine)
作者：Kristian A Haanes* (Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet-Glostrup, Denmark)
2. 手术切除的Merkel细胞癌患者是否应使用纳武利尤单抗辅助治疗?
(Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?)
作者：Philippe Saiag* (Department of General and Oncologic Dermatology, Ambroise Paré Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, France)

ARTICLES（文章）
3. Atogepant用于慢性偏头痛的预防性治疗(进展)：一项随机，双盲，安慰剂对照的3期试验
(Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial)
作者：Patricia Pozo-Rosich* (Vall d'Hebron University Hospital and Headache & Neurological Pain Research Group, Vall d'Hebron Institute of Research, Universitat Autonoma of Barcelona, Spain)4.纳武利尤单抗辅助免疫治疗与完全切除Merkel细胞癌(ADMEC-O)的观察:一项随机、开放标签、2期试验的无病生存期结果
(Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial)
作者：Jürgen C Becker, Dirk Schadendorf* (Department of Dermatology, University Hospital Essen, Germany)

（二）09 September 2023 - Volume 402 - Issue 10405 (2023年9月9日第402卷第10405期)
https://www.thelancet.com/journals/lancet/issue/vol402no10405/PIIS0140-6736(23)X0036-1

COMMENT（评论）
1. 加用COX-2抑制剂可提高紧急避孕的疗效
(Adding a COX-2 inhibitor improves efficacy of emergency contraception)
作者：Erica P Cahill* (Department of Obstetrics and Gynecology, Division of Family Planning Services and Research, Stanford University School of Medicine, USA)

ARTICLES（文章）
2. 口服紧急避孕药左炔诺孕酮联合吡罗昔康：一项随机双盲安慰剂对照试验
(Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial)
作者：Raymond Hang Wun Li* (Department of Obstetrics and Gynaecology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, China)
3. 布地奈德靶向缓释制剂治疗原发性IgA肾病的有效性和安全性：一项为期2年的随机3期试验结果
(Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial)
作者：Richard Lafayette* (Division of Nephrology, Department of Medicine, Stanford University, USA)

（三）16 September 2023 - Volume 402 - Issue 10406 (2023年9月16日第402卷第10406期)
https://www.thelancet.com/journals/lancet/issue/vol402no10406/PIIS0140-6736(23)X0037-3

COMMENT（评论）
1. 溶栓是否增加了急性缺血性卒中血栓切除术的价值？
(Does thrombolysis add value to thrombectomy for acute ischaemic stroke?)
作者：Graeme J Hankey* (Perron Institute for Neurological and Translational Science, Australia)

ARTICLES（文章）
2. 静脉溶栓在大血管前循环卒中血管内治疗的价值：6项随机试验的个体受试者数据meta分析
(Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials)
作者：Charles B Majoie* (Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Netherlands)

（四）23 September 2023 - Volume 402 - Issue 10407 (2023年9月23日第402卷第10407期)
https://www.thelancet.com/journals/lancet/issue/vol402no10407/PIIS0140-6736(23)X0038-5

ARTICLES（文章）
1. 肾细胞癌（EVEREST）手术后的依维莫司辅助治疗：一项双盲、安慰剂对照、随机、3期试验
(Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial)
作者：Christopher W Ryan* (Oregon Health and Science University Knight Cancer Institute, USA)

（五）30 September 2023 - Volume 402 - Issue 104087 (2023年9月30日第402卷第10408期)
https://www.thelancet.com/journals/lancet/issue/vol402no10408/PIIS0140-6736(23)X0039-7

ARTICLES（文章）
1. 卡瑞利珠单抗联合rivoceranib与甲苯磺酸索拉非尼作为不可切除肝细胞癌（CARES-310）的一线治疗：一项随机、开放标签的国际3期研究
(Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study)
作者：Shukui Qin* (Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine and Nanjing Medical University, China)

三、新英格兰医学杂志 (2023年9月第389卷第10-13期)

（一）7 September 2023 - Volume 389 - No 10 (2023年9月7日第389卷第10期)
https://www.nejm.org/toc/nejm/389/10

ORIGINAL ARTICLES（原创文章）
1. 每日口服GLP-1受体激动剂Orforglipron治疗成人肥胖症
(Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity)
作者：Sean Wharton, Manige Konig* (McMaster University, York University, and Wharton Weight Management Clinic, Canada; Eli Lilly, USA)
2. 阿替利珠单抗治疗晚期腺泡状软组织肉瘤
(Atezolizumab for Advanced Alveolar Soft Part Sarcoma)
作者：Alice P. Chen*, Elad Sharon ( the Division of Cancer Treatment and Diagnosis, Maryland)

EDITORIALS（社论）
3. 体重控制的下一章—小分子GLP-1受体激动剂？
(Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?)
作者：E. Dale Abel (the Department of Medicine, David Geffen School of Medicine, University of California, USA)

CORRESPONDENCE（通信）
4. 司美格鲁肽治疗早期1型糖尿病
(Semaglutide in Early Type 1 Diabetes)
5. 氯胺酮与 ECT 治疗非精神病性难治性重度抑郁症的比较
(Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression)

（二）14 September 2023 - Volume 389 - No 11 (2023年9月14日第389卷第11期)
https://www.nejm.org/toc/nejm/389/11

ORIGINAL ARTICLES（原创文章）
1. 羧麦芽糖铁在缺铁型心力衰竭中的应用
(Ferric Carboxymaltose in Heart Failure with Iron Deficiency)
作者：Robert J. Mentz* (the Division of Cardiology, Department of Medicine, Duke University School of Medicine, USA)
2. III、IV或V级膀胱输尿管反流婴儿的抗生素预防
(Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux)
作者：William Morello, Giovanni Montini* (the Pediatric Nephrology, Dialysis, and Transplant Unit,  Italy)
3. FGF21类似物Pegozafermin在NASH中的随机对照试验
(Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH)
作者：Rohit Loomba* (he NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California, USA)
4. Mezigdomide联合地塞米松治疗复发性和难治性多发性骨髓瘤
(Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma)
作者：Paul G. Richardson (the Department of Medical Oncology, Dana–Farber Cancer Institute ,USA)

EDITORIALS（社论）
5. 心力衰竭中铁缺乏的治疗
(Treating Iron Deficiency in Heart Failure)
作者：Pieter Martens (the Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, and the Faculty of Medicine and Life Sciences, Hasselt University, Belgium)
6. 膀胱输尿管反流的选择性抗菌预防
(Selective Antimicrobial Prophylaxis for Vesicoureteral Reflux)
作者：Tej K. Mattoo (the Department of Pediatrics, Wayne State University School of Medicine, USA)
7. Mezigdomide和多发性骨髓瘤
(Mezigdomide and Multiple Myeloma)
作者：Jake Shortt (the Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing, and Health Sciences, Monash University, and Monash Haematology, Monash Health, Australia)

CORRESPONDENCE（通信）
8. 妊娠期二价预融合F疫苗可预防婴儿RSV疾病
(Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants)

（三）21 September 2023 - Volume 389 - No 12 (2023年9月21日第389卷第12期)
https://www.nejm.org/toc/nejm/389/12

ORIGINAL ARTICLES（原创文章）
1. 司美格鲁肽在保留射血分数和肥胖的心力衰竭患者中的应用
(Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity)
作者：Mikhail N. Kosiborod* (Saint Luke’s Mid America Heart Institute, Denmark)
2. 吸入糠酸氟替卡松用于Covid-19的门诊治疗
(Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19)
作者：David R. Boulware, Susanna Naggie* (the University of Minnesota, USA; the Duke Clinical Research Institute, Duke University School of Medicine, USA)
3. Solanezumab在临床前阿尔茨海默病中的试验
(Trial of Solanezumab in Preclinical Alzheimer’s Disease)
作者：Reisa A. Sperling, Paul S. Aisen* (the Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, USA;the USC Alzheimer’s Therapeutic Research Institute, USA)
4. 达拉非尼联合曲美替尼治疗BRAF V600突变的儿科胶质瘤
(Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations)
作者：Eric Bouffet* (the Hospital for Sick Children, Canada)

CORRESPONDENCE（通信）
5. 军事人员接种天花疫苗预防Mpox的效果
(Effectiveness of Smallpox Vaccination to Prevent Mpox in Military Personnel)
6. 睾酮替代疗法的心血管安全性
(Cardiovascular Safety of Testosterone-Replacement Therapy)
7. 使用芦可替尼或贝舒地尔治疗后的皮肤癌
(Skin Cancer after Ruxolitinib or Belumosudil)

（四）28 September 2023 - Volume 389 - No 13 (2023年9月28日第389卷第13期)
https://www.nejm.org/toc/nejm/389/13

PERSPECTIVE（视角）
1. 非洲地区的青蒿素耐药性和HRP阴性疟疾寄生虫
(Artemisinin-Resistant and HRP-Negative Malaria Parasites in Africa)
作者：Brian Greenwood (the Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK)

ORIGINAL ARTICLES（原创文章）
2. 依度沙班抗凝治疗心房高频率发作患者
(Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes)
作者：Paulus Kirchhof* (the Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg–Eppendorf, Germany)
3. 在厄立特里亚，对青蒿素耐药的hrp2阴性疟疾流行率不断上升
(Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea)
作者：Selam Mihreteab*, Didier Ménard* (the National Malaria Control Program, Eritrea; the Institute of Parasitology and Tropical Diseases, Dynamics of Host–Pathogen Interactions, Université de Strasbourg, France)

CORRESPONDENCE（通信）
4. Bulevirtide治疗慢性丁型肝炎
(Bulevirtide for Chronic Hepatitis D)

四、美国医学会杂志 (2023年9月第330卷第9-12期)

（一）5 September 2023 -Volume 330 - No.9 (2023年9月5日第330卷第9期)
https://jamanetwork.com/journals/jama/issue/330/9

Original Investigation（原始调查）
1. 单剂量裸盖菇素治疗重度抑郁症：一项随机临床试验
(Single-Dose Psilocybin Treatment for Major Depressive Disorder:A Randomized Clinical Trial)
作者：Charles L. Raison (Usona Institute, USA)

Comment & Response（评论与回复）
2. 用于创伤患者的四因子凝血酶原复合物浓缩物
(Four-Factor Prothrombin Complex Concentrate for Patients With Trauma)
作者：Chia-Hao Hsu (Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Taiwan, China)
3. 用于创伤患者的四因子凝血酶原复合物浓缩物
(Four-Factor Prothrombin Complex Concentrate for Patients With Trauma)
作者：Tomohiko Sat (Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Japan)
4. 用于创伤患者的四因子凝血酶原复合物浓缩物——作者回复
(Four-Factor Prothrombin Complex Concentrate for Patients With Trauma—Reply)
作者：Pierre Bouzat (Universite Grenoble Alpes, CHU Grenoble Alpes, France)

（二）12 September 2023 -Volume 330 - No.10 (2023年9月12日第330卷第10期)
https://jamanetwork.com/journals/jama/issue/330/10

Original Investigation（原始调查）
1. 心房颤动导管消融术与药物治疗和心理困扰：一项随机临床试验
(Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial)
作者：Ahmed M. Al-Kaisey (Department of Cardiology, Royal Melbourne Hospital, Australia)

Medical News & Perspectives（医学新闻和观点）
2. 一种速效药丸获批用于产后抑郁症——它会改变游戏规则吗？
(A Fast-Acting Pill Received Approval for Postpartum Depression—Is It a Game Changer?)
作者：Rita Rubin

Comment & Response（评论与回复）
3. 泼尼松与复发性移植失败患者的活产率
(Prednisone and Live Birth Rate in Patients With Recurrent Implantation Failure)
作者：Marcelo Borges Cavalcante (Postgraduate Program in Medical Sciences, Universidade de Fortaleza (UNIFOR), Brazil)
4. 泼尼松龙和复发性移植失败患者的活产率
(Prednisone and Live Birth Rate in Patients With Recurrent Implantation Failure)
作者：Genia Rozen (Obstetrics and Gynaecology Department, Melbourne University, Australia)
5. 泼尼松龙和复发性移植失败患者的活产率——作者回复
(Prednisone and Live Birth Rate in Patients With Recurrent Implantation Failure—Reply)
作者：Yao Lu (Center for Reproductive Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China)

（三）19 September 2023 -Volume 330 - No.11 (2023年9月19日第330卷第11期)
https://jamanetwork.com/journals/jama/issue/330/11

Original Investigation（原始调查）
1. 微创表面活性剂治疗早产儿的2年预后：OPTIMIST-A随机临床试验的随访
(Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial)
作者：Peter A. Dargaville (Menzies Institute for Medical Research, University of Tasmania, Australia)
2. 采用阿莫西林-克拉维酸与阿莫西林治疗小儿急性鼻窦炎后的治疗失败和不良事件
(Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis)
作者：Timothy J. Savage (Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, USA)

Preliminary Communication（初步沟通）
3. Muvalaplin，一种口服小分子脂蛋白(a)形成抑制剂：一项随机临床试验
(Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial)
作者：Stephen J. Nicholls (Victorian Heart Institute, Monash University, Australia)

Medical News in Brief（医学新闻简讯）
4. FDA批准孕妇接种RSV疫苗
(FDA Approves Maternal RSV Vaccine)
作者：Emily Harris
5. 青蒿素耐药性增加
(Artemisinin Resistance Increasing)
作者：Emily Harris

Comment & Response（评论与回复）
6. 哌拉西林-他唑巴坦与头孢西丁用于胰十二指肠切除术围手术期预防
(Piperacillin-Tazobactam vs Cefoxitin Prophylaxis for Pancreatoduodenectomy)
作者：Romain Jouffroy (Service de Médecine Intensive Réanimation, Hôpital Universitaire Ambroise Paré, France)
7. 哌拉西林-他唑巴坦与头孢西丁用于胰十二指肠切除术围手术期预防
(Piperacillin-Tazobactam vs Cefoxitin Prophylaxis for Pancreatoduodenectomy)
作者：Ziyi Yang (Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China)
8. 哌拉西林-他唑巴坦与头孢西丁用于胰十二指肠切除术围手术期预防
(Piperacillin-Tazobactam vs Cefoxitin Prophylaxis for Pancreatoduodenectomy)
作者：Robert G. Sawyer (Western Michigan University Homer Stryker MD School of Medicine, USA)
9. 哌拉西林-他唑巴坦与头孢西丁用于胰十二指肠切除术围手术期预防——作者回复
(Piperacillin-Tazobactam vs Cefoxitin Prophylaxis for Pancreatoduodenectomy—Reply)
作者：Ryan J. Ellis (Memorial Sloan Kettering Cancer Center, USA)

（四）26 September 2023 -Volume 330 - No.12 (2023年9月26日第330卷第12期)
https://jamanetwork.com/journals/jama/issue/330/12

Original Investigation（原始调查）
1. Lorundrostat抑制醛固酮合酶用于治疗难治性高血压：Target-HTN 随机临床试验
(Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension:The Target-HTN Randomized Clinical Trial)
作者：Luke J. Laffin (Cleveland Clinic Foundation, USA)

Medical News in Brief（医学新闻简讯）
2. 司美格鲁肽改善心力衰竭和心血管疾病
(Semaglutide Improves Heart Failure and Cardiovascular Disease)
作者：Emily Harris

Comment & Response（评论与回复）
3. 减少慢性疼痛患者阿片类药物使用的团体干预
(A Group-Based Intervention to Reduce Opioid Use for Chronic Pain)
作者：Jane Quinlan (Oxford University Hospitals Trust, England)
4. 减少慢性疼痛患者阿片类药物使用的团体干预——作者回复
(A Group-Based Intervention to Reduce Opioid Use for Chronic Pain—Reply)
作者：Harbinder K. Sandhu (Warwick Medical School, University of Warwick, England)

五、自然：药物发现综述 (2023年9月第22卷)

（一）September 2023 - Volume 22 - Issue 9 (2023年9月第22卷第9期)
https://www.nature.com/nrd/volumes/22/issues/9

NEWS IN BRIEF（新闻简讯）
1. FDA批准长效RSV抗体
(FDA approves long-acting RSV antibody)
作者：Asher Mullard

RESEARCH HIGHLIGHT（研究亮点）
2. 拓扑异构酶II抑制剂治愈锥虫感染
(Topoisomerase II inhibitor cures trypanosome infections)
作者：Sarah Crunkhorn
3. 多肽疫苗可提高ALK阳性癌症的热度
(Peptide vaccine turns up the heat in ALK-positive cancers)
作者：Alex Eccleston

六、自然：免疫学综述 (2023年9月第23卷第9期)

September 2023 - Volume 23 - Issue 9  (2023年9月第23卷第9期)
https://www.nature.com/nri/volumes/23/issues/9

七、柳叶刀：呼吸医学 (2023年9月)

September 2023 - Volume 11 - Number 9  (2023年9月第11卷第9期)
https://www.thelancet.com/journals/lanres/issue/vol11no9/PIIS2213-2600(23)X0009-5

Article（文章）
1. 含利福平或利福喷丁的结核病预防性治疗方案的完成率、安全性和有效性：一项个体化患者数据网络Meta分析
(Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis)
作者：Nicholas Winters, Dick Menzies* (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada; McGill University, Canada)
2. 在美国静脉注射aviptadil和瑞德西韦治疗COVID-19 相关性低氧性呼吸衰竭（TESICO）：一项随机、安慰剂对照试验
(Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial)
作者：Samuel M Brown* (Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, USA)

八、英国医学期刊 (2023年9月第382卷第8396-8400期)

（一）02 September 2023 - Volume 382 - Issue 8396 (2023年9月2日第382卷第8396期)
https://www.bmj.com/content/382/8396

Letters（信件）
1. 没有证据表明维生素D可以预防心血管事件
(There is no evidence that vitamin D prevents cardiovascular events)
作者：Naveed Satta (University of Glasgow, UK)
2. 研究结果表明，维生素D在预防主要心血管事件方面约有99%无效
(Study results show vitamin D is around 99% ineffective in preventing major cardiovascular events)
作者：Joachim Sturmberg

（二）9 September 2023 - Volume 382 - Issue 8397 (2023年9月9日第382卷第8397期)
https://www.bmj.com/content/382/8397

Research（研究）
1. 使用激素避孕和非甾体抗炎药对静脉血栓栓塞：全国队列研究
(Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study)
作者：Amani Meaidi* (Department of Gynecology, Rigshospitalet, University of Copenhagen, Denmark)

Editorials（社论）
2. 非甾体抗炎药、激素避孕和静脉血栓栓塞
(NSAIDs, hormonal contraception, and venous thromboembolism)
作者：Morten Schmidt (Department of Clinical Epidemiology, Aarhus University Hospital, Denmark)

Practice（实践）
3. 针对艾滋病毒的双药抗逆转录病毒治疗方案
(Two-drug antiretroviral regimens for HIV)
作者：John P Thornhill* (Blizard Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, UK)

（三）16 September 2023 - Volume 382 - Issue 8398 (2023年9月16日第382卷第8398期)
https://www.bmj.com/content/382/8398

News（新闻）
1. 替尔泊肽：NICE推荐另一种GLP-1激动剂治疗2型糖尿病
(Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes)
作者：Elisabeth Mahase

（四）23 September 2023 - Volume 382 - Issue 8399 (2023年9月23日第382卷第8399期)
https://www.bmj.com/content/382/8399

News（新闻）
1. NICE 推荐瑞美吉泮用于治疗成人急性偏头痛
(NICE recommends rimegepant for treating acute migraine in adults)
作者：Gareth Iacobucci

Research（研究）
2. 灭活病毒颗粒疫苗BIV1-CovIran对SARS-CoV-2的有效性和安全性：随机、安慰剂对照、双盲、多中心、3期临床试验
(Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial)
作者：Minoo Mohraz, Mohammadreza Salehi* (Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Iran; Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran)

（五）30 September 2023 - Volume 382 - Issue 8400 (2023年9月23日第382卷第8400期)
https://www.bmj.com/content/382/8400

Research（研究）
1. 与老年人心血管事件相关的抗胆碱能药物
(Anticholinergic medicines linked to cardiovascular events in older adults)
作者：Tou-Yuan Tsai, Huei-Kai Huang* (School of Medicine, Tzu Chi University, Taiwan, China)

Education（教育）
2. 2型糖尿病儿童和青少年患者的血糖监测和降糖剂：NICE更新指南摘要
(Glucose monitoring and glucose lowering agents for children and young people with type 2 diabetes: summary of updated NICE guidance)
作者：Linyun Fou* (National Institute for Health and Care Excellence (NICE), UK)

九、自然：医学 (2023年9月第29卷第9期)

September 2023 - Volume 29 - Issue 9 (2023年9月第29卷第9期)
https://www.nature.com/nm/volumes/29/issues/9

NEWS（新闻）
1. FDA批准辉瑞的JAK抑制剂用于青少年斑秃脱发
(FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss)
作者：Thiago Carvalho

Article（文章）
1. Elranatamab治疗复发或难治性多发性骨髓瘤：MagnetisMM-3 2期试验结果
(Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results)
作者：Alexander M. Lesokhin* (Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, USA)
2. 儿童期癌症使用蒽环类药物化疗与女性患乳腺癌后续风险相关
(Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer)
作者：Yuehan Wang* (Princess Máxima Center for Pediatric Oncology, The Netherlands)
3. 伊匹木单抗联合或不联合纳武利尤单抗治疗PD-1或PD-L1阻断难治性转移性黑色素瘤：一项随机2期试验
(Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial)
作者：Ari VanderWalde* (The West Clinic-Wolf River, USA)
4. Idecabtagene vicleucel 治疗复发和难治性多发性骨髓瘤：1期试验的18个月事后随访
(Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial)
作者：Yi Lin* (Mayo Clinic, USA)
5. 原始SARS-CoV-2单价疫苗和奥密克戎BA.4/BA.5二价COVID-19 mRNA疫苗：2/3期试验中期结果
(Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results)
作者：Spyros Chalkias* (Moderna, Inc., USA)
6. 二价和一价SARS-CoV-2变异疫苗的比较：2期随机开放标签COVAIL试验
(Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial)
作者：Angela R. Branche¹*, Nadine G. Rouphael², Paul C. Roberts³, John H. Beigel⁴ (1.Department of Medicine, Division of Infectious Diseases, University of Rochester, USA; 2. Hope Clinic, Emory University, Decatur, USA; 3. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; 4. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA)
7. 司美格鲁肽治疗不同肥胖级别和体重减轻程度的HFpEF:一项对STEP-HFpEF试验的预设分析
(Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial)
作者：Barry A. Borlaug, Mikhail N. Kosiborod* (Department of Cardiovascular Medicine, Mayo Clinic, USA; Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, USA)

十、世界精神病学 (2023年第22卷第3期)

（一）2023 - Volume 22 - Issue 3 (2023年第22卷第3期)
https://onlinelibrary.wiley.com/toc/20515545/2023/22/3